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Intervertebral disc degeneration (IVD) is a frequent pathological condition. Conservative management often fails, and patients
with IVD degeneration may require surgical intervention. Several treatment strategies have been proposed, although only surgical
discectomy and arthrodesis have been proved to be predictably eﬀective. The aim of biological strategies is to prevent and manage
IVD degeneration, improve the function, the anabolic and reparative capabilities of the nucleus pulposus and annulus ﬁbrosus
cells, and inhibit matrix degradation. At present, clinical applications are still in their infancy. Further studies are required to
clarify the role of mesenchymal stem cells and gene therapy for the prevention and treatment of IVD degeneration.
1.Introduction
The normal intervertebral disc (IVD) has a rich extracellular
matrix (ECM), and three parts are anatomically distin-
guished:thecentralgelatinousnucleuspulposus(NP),which
containschondrocyte-likecellssurroundedbyamoreﬁbrous
annulus ﬁbrosus (AF) containing ﬁbroblast-like cells along
with cartilaginous endplates (EP) connecting the adjacent
vertebral bodies [1–6].
The IVD matrix consists of a well-organized framework
of macromolecules which are able to attract and retain
water [7]. The structural components of the IVD matrix are
predominantly represented by collagen and proteoglycans
[8]. Collagenous proteins are mostly present in the AF, and
proteoglycans are the major components of the NP. In fact,
collagenous proteins comprise 70% of the outer annulus dry
weight, but only 20% are located in the central NP, while
proteoglycans make up 50% of the NP [8].
Functionally, the collagen provides shape and tensile
strength, while proteoglycans confer tissue viscoelasticity,
stiﬀness, and resistance to compression, through their inter-
action with water.
A proper balance between matrix synthesis/apposition
and degradation is responsible for the maintenance of the
integrity of the IVD and hence the mechanical behaviour
of the IVD itself. This is related to the activity of cytokines,
growth factors, enzymes, and enzyme inhibitors that act in a
paracrine or/and autocrine way [9–11].
With aging, morphological and molecular changes in
the IVD can induce progressive degeneration and pathologic
alteration of this particular tissue [12]. The morphological
changes include dehydration and tears of the AF, NP, and
EP [13]. The molecular changes consist of decreased cell
viability and proteoglycans synthesis and reduced diﬀusion
of nutrient and waste products. Accumulation of apoptosis
debris, degraded matrix macromolecules, and an increased
degrading enzymatic activity along with a modiﬁcation of
the collagen distribution also represent the degenerative
changes that occur at a molecular level [8, 11, 14–16].2 Stem Cells International
AvarietyofgrowthfactorshaveanabolicfunctioninIVD
cell metabolism, resulting in accumulation and synthesis
of matrix, while the opposite eﬀect has been observed for
cytokines, since they inhibit the synthesis of IVD matrix and
promotethecatabolicbreakdownofitscomponents[11,17].
Although inﬂammatory mediators have been detected
in IVD degeneration conditions, the actual pathologic role
of these mediators is either unknown or not well deﬁned.
Nitric oxide (NO), interleukin-6 (IL-6), prostaglandin E2
(PGE2), TNF-alpha, ﬁbronectin, and matrix metallopro-
teinases (MMPs) are few of the many identiﬁed mediators
[12, 13, 18, 19].
IL-6, NO, and PGE2 seem to exert an inhibitory eﬀect
on proteoglycan synthesis. These factors are activated by
interleukin-1 (IL-1), which also plays a role in the direct
degradation of the proteoglycan matrix. This direct break-
down process by IL-1 occurs through a family of enzymatic
mediators known as MMPs. In the cascade of inﬂammatory
mediators, IL-1 likely plays a major role, although the nature
of such role has not been deﬁned yet.
To ﬁnd new eﬃcient treatment options, further investi-
gations are required to identify the mediators that promote
IVD degradation or matrix accumulation with the aim of
targetingthehomeostaticstateofIVD-matrixmetabolismby
modulatingthefactorsinvolvedinsynthesisanddegradation
towards the most favourable state to ensure their metabolic
balance. Only recently, considerable attention has been
placed on the use of stem cells as a clinically applicable
therapeutic option for IVD degeneration.
The aim of this paper was to report the state of the
art on the treatment of IVD degeneration (IVD-d), with
mesenchymal stem cells (MSCs) based on the in vitro and
in vivo experiences currently available.
2. IVD Degeneration
An active regulation and balance between anabolism and
catabolism of the IVD cells is responsible for the mainte-
nance of the physiological homeostasis in IVD tissue.
This mechanism is guaranteed through a complex and
accurate coordination of the eﬀect of a number of substances
and molecules, including growth factors, enzymes, enzyme
inhibitors, and cytokines, that act in a paracrine or/and
autocrine way.
IVD degeneration commonly begins during the second
decade of life, and it progresses towards severe conditions
with ageing [17].
The lack of an adequate nutrient supply [8], along with
the inappropriate mechanical load [20], may cause loss and
a l t e r a t i o n ,a sw e l la sd y s f u n c t i o n ,o fc e l lv i a b i l i t ya n dI V D
properties.
IVDherniation,radiculopathy,myelopathy,spinalsteno-
sis, instability, and low back pain represent the common
medical conditions usually associated with symptomatic
IVD-d, and they represent the most common among the
conditions managed by spine surgeons, in addition to being
theleadingcauseofdisabilityinpeopleyoungerthan45years
of age.
Various therapeutic strategies have been proposed for
IVD-d in the last decade, with the most frequently used
ones consisting of surgical interventions characterized by
discectomy with vertebral fusion or, as an alternative,
conservative management of IVD-d (e.g., lifestyle changes,
physical therapy, pain medication, rehabilitation). Neither
of such approaches deals with the loss of IVD tissue, and
therefore new biological strategies appear challenging.
3. MSCs in IVD Degeneration (IVD-d)
Researchers and clinicians have focused their attention on
tissue engineering and regenerative medicine to identify
long-term tissue repairing options oﬀering the possibility to
restore IVD tissues [21].
Attention has been posed on stem cells as a potential
source of cells to repopulate and regenerate the IVD. There
is a large number of potential sources of MSCs, including
adipose tissue, bone marrow, and other tissues [22, 23]
as embryonic and fetal stem cells, which are pluripotent
cells with a potential to diﬀerentiate into any body tissue.
Regarding the embryonic stem cells, these cells are highly
ﬂexible since they are able to diﬀerentiate into any type of
tissue, but both the procurement of human embryonic stem
cells and research are limited, given the related ethical issues
[24].
In terms of IVD regeneration, many studies have shown
that IVD-d can be treated or repaired with the injection of
MSCs, multipotent cells able to diﬀerentiate into tissues of
mesenchymal origin including bone, cartilage, fat, muscle,
andﬁbroustissuesdependingonthebiologicalenvironment.
These cells can be obtained from multiple adult tissues,
including bone marrow, trabecular bone, articular cartilage,
muscle, and adipose tissue, which represent a variant of the
adult stem cell.
Several authors have speculated that MSCs can also
diﬀerentiate into the chondrocyte-like cells present in the
NP, but, since the phenotype of NP cells has not been
clearly characterized yet, conﬁrmation of the diﬀerentiation
from MSCs to NP cells has not been achieved [23, 25, 26],
mainly because AF, NP, and EPs components have a diﬀerent
cartilage or bone composition and diﬀerent kinds of matrix
macromolecules and proteins.
While a variety of cell sources in the ﬁeld of stem cell
research have been proposed for clinical application [21],
autologous adipose stem cells (ASCs) as a cell source in bone
and cartilage repair have gained signiﬁcant attention. In fact,
adipose tissue is considered a suitable source of stem cells for
clinical use, given the easiness of the procedure to retrieve
adipose tissue, since this procedure is minimally invasive and
can be performed in outpatient clinics and also due to the
larger number of cells obtained [27]. Treatment or repair
of IVD can occur with an injection of autologous adipose
stem cells (ASCs), in presence or absence of growth factor
prestimulation or matrix attachment [28].Stem Cells International 3
4.MesenchymalStemCells (MSCs)
4.1. In Vitro Evidences on MSCs. Based on the high incidence
of symptomatic IVD-d caused by disc herniation, radicu-
lopathy, myelopathy, spinal stenosis, instability, and low back
pain, there is a great interest around the use of MSCs to
repair degenerated IVD tissues. Since the IVD phenotype of
NP cells has not been clearly deﬁned yet, there is still a lack
of knowledge about diﬀerentiation from MSCs to NP cells,
complicated by the fact that AF, NP, and EPs components are
diﬀerently composed of cartilage or bone and matrix.
Nevertheless, in vitro experiments have demonstrated
that the application of growth factors and speciﬁc culture
conditions can guide MSCs to diﬀerentiate into particular
cell phenotypes [29].
In an in vitro study conducted with MSCs cultured
in the presence of TGF-b, it was observed that the MSCs
were able to express a phenotype similar to NP cells with
the production of type II collagen and aggrecan [30].
Moreover, under speciﬁc culture conditions such as hypoxia,
it was initially seen that hypoxia contributed to maintain
an NP cell phenotype in in vitro cultures, and subsequently
the combination of hypoxia and TGF-b1 exposure proved
to advance diﬀerentiation of the MSCs into an NP-like
phenotype. On the basis of this experience, researchers
suggested that the hypoxic environment of the IVD could
promote diﬀerentiation of the MSCs towards an NP-like
phenotype in vivo [31, 32].
The eﬀe c to fc o c u l t u r e so fM S C sw i t hA Fa n dN Pc e l l s
obtained from human degenerative IVDs in 3-dimensional
pellet cultures has also been investigated. The coculture
determined an increased proliferation in both the MSC-AF
andMSC-NP cultures,butahigher proteoglycanproduction
was found only in the MSC-AF coculture. Based on the
interactionbetweenAFcellsandMSCs,adirectimplantation
of the MSCs in vivo may be applied without any need to
diﬀerentiate the MSCs before implantation [33].
In their research in the IVD implantation of MSCs, Sakai
et al. [34–36] initially implanted MSCs into a normal IVD
and subsequently repeated the same experiment in a IVD
degeneration model in rabbit. Based on the results obtained
in their initial study, they reported that autologous MSCs
implanted into a rabbit IVD survive and proliferate, with
diﬀerentiation into a NP-like phenotype. At 48 weeks since
implantation, labelled MSCs (i.e., tagged with the gene for
green ﬂuorescent protein (GFP) with the GFP-labelled cells
followed tracking their eﬀects for a period of 48 weeks)
expressed factor-a (HIF-a), glutamine transporter-1, and
MMP-2, which represent hypoxia-inducible NP phenotypic-
relatedmarkers[36].AutologousMSCsinjectedintotheIVD
could reestablish a chondrocyte-like cell population able to
produce proteoglycans and collagen II in a rabbit degener-
ating IVD. At MRI imaging, degenerating IVDs treated with
MSCs showed improvement compared to controls both in
IVD height and hydration [35].
To repair the matrix of degenerative NP tissue, trans-
planted cells must produce large quantities of collagen, pro-
teoglycans (e.g., aggrecan), and other matrix proteins [37].
Generally,thesematrixproteinsareproducedbycellslocated
in the central regions of the IVD and chondrocytes, making
them candidates for cell-based IVD repair. Also, progress
recorded in stem cell research in the past decade provides
an attractive scenario for the use of adult MSCs (ASCs) for
NPtissueengineering [30,38–46].Thereafter,whileavariety
of cell sources in the ﬁeld of stem cell research has been
proposed for clinical application [21], ASCs as a cell source
inboneandcartilagerepairhavegainedsigniﬁcantattention.
Particularly, application of ASCs in NP tissue regeneration
has been the subject of a number of recent studies [27, 47–
49]. One study reported that the diﬀerentiation of ASCs into
a NP cell-like phenotype occurred in coculture of human
ASCs and NP cells in a micro-mass-cultured mode. In
other experiments, expression of proteoglycan and type I
collagen in 3D-cultured sand rat ASCs could be signiﬁcantly
stimulated either through treatment of TGF-b or coculture
of human IVD cells [27, 49].
Moreover, in coculture of NP cells and ASCs combined
in micromasses, separated by a permeable membrane to
allow the diﬀusion of soluble factors, an upregulation of
the aggrecan and collagen II expression was detected [50].
Therefore, soluble factors released by NP cells may have a
directeﬀectonpromoting thediﬀerentiation of the ASC into
the NP-type lineage [51].
Coculture of human NP and ASCs improves the quality
of the tissue reconstructed in vitro both in terms of 3D
cell organization and matrix production [47]. Conversely,
cell expansion is essentially needed to obtain suﬃcient cell
quantities for transplantation, and the common monolayer
culture approach has determined a number of concerns
including cell dediﬀerentiation, senescence, and genetic
mutagenesis [40].
However, adipose tissue might be considered as an
adequate source of stem cells for clinical use, based both on
the ease of the procedure to retrieve adipose tissue and the
cell quantities that can be obtained. In fact, on one hand,
the collection of adipose tissue occurs through a minimally
invasive procedure allowing for this to be straightforwardly
performed in outpatient clinics, and, on the other hand, it
allows for yields of adherent ASCs to reach up to 25,000/g
of tissue. Therefore, although somewhat new in the stem cell
research area, ASCs have gained intensive attention as a cell
source in bone and cartilage repair [27] and the use of ASCs
as seed cells in NP tissue engineering has been the subject of
further investigations [52, 53].
The results of cocultured rabbit ASCs with NP tissues
through a speciﬁcally designed device showed that ASCs
responded to soluble mediators from NP tissues [53]. In
experimental studies, NP or AF tissues were cocultured
with alginate beads containing ASCs isolated from inguinal
fad pads of NZW rabbits and following real-time RT-PCR
analysis and it was observed that NP tissues could notably
stimulate type II collagen and aggrecan genes expression in
ASCs, whereas this was not the case for AF tissues [53].
Recently, conﬁrmation of the feasibility of a stem cell
therapy for IVD repair has been obtained by a parallel in
vitro and in vivo study. In the in vitro portion of the study, in
which bone-marrow-derived stem cells (BSCs) and IVD cells
werecocultured,theresultsshowedanimprovementofECM4 Stem Cells International
production, while the in vivo study persistence of BSC for at
least 24 weeks after implantation in rabbit IVD was shown
[54].
4.2. In Vivo Evidences on MSCs. The future of treatment
o p t i o n sf o rI V Dd e g e n e r a t i o ns h o u l dd e a lw i t he v i d e n c e s
regarding the use of MSCs in animal studies.
The possibility of allogeneic MSC transplantation has
also been suggested and should be considered [55], based
on a number of potential advantages of allograft stem cells
versus autograft stem cells.
It is theorized that the use of autograft MSCs may have
the same genetic predisposition for degeneration as the
native NP cells, while it should be possible to escape this
genetic predisposition by using an allograft cell population.
The use of allograft MSCs may in fact allow for the selection
and maintenance of a cell population that is less likely to
undergo degeneration. Also, in comparison to collection and
culture of MSCs for each individual patient, allograft cells
could be maintained for “oﬀ the shelf use” with a higher
convenience and reduced costs [24].
Several in vivo animal experiments conducted with the
implant of MSCs into the IVD have highlighted promising
results in terms of long-term viability of the implanted cells
and diﬀerentiation into a phenotype similar to the native NP
cells with the production of type II collagen and aggrecan
[24].
Crevensten et al. [56] were the ﬁrst in 2004 to report
the viability of allograft MSCs implanted in a rat IVD.
They observed the proliferation of the stem cells as well
as a trend towards increased IVD height after a 4-week
follow-up period, which suggested an enhanced production
of proteoglycans.
Subsequently, allograft MSCs were also transplanted into
theNewZealandwhiterabbit:thecellssurvived,proliferated,
and diﬀerentiated into native NP cells like phenotype. After
grafting, the animals were followed for 6 months, and no
immune reactions occurred towards these allograft cells. In
the IVDs treated with MSCs, type II collagen production
along with an increased proteoglycan concentration was
detected [57].
The eﬀectiveness of MSC transplantation has also been
conﬁrmed in large animal models (chondrodystrophoid
breed canine with nucleotomy) closer to humans. In fact, in
a canine model of IVD degeneration, MSC transplantation
determined a positive outcome on preservation of immune
privilege, possibly by diﬀerentiation of the transplanted
MSCs into FasL expressing cells [38]. These data suggest that
the NP region may tolerate MSCs from other areas of the
body or even other individuals [58].
Other researchers have also investigated the use of
allogenic MSCs for IVD regeneration, despite the concerns
for immunologic rejection of the allograft tissue. Similarly to
previousexperiencesshowing invivo viabilityofallograftNP
tissue, the “immunologically privileged” environment of the
avascular IVD space may also allow for long-term viability of
allograft stem cells [59, 60].
The ability of allogenic MSCs to escape alloantigenic
immune recognition and determine an immunomodulatory
eﬀect has been noted also in other studies [61, 62]. The
ability to elude immune recognition may arise from the lack
of major histocompatibility complex class II molecules on
MSCs. Nevertheless, major histocompatibility complex class
II expression has been observed as MSCs diﬀerentiate or are
exposed to inﬂammatory cytokines [61, 62].
An immunomodulatory eﬀect of MSCs on the local
environment by producing anti-inﬂammatory cytokines
such as TGF-b and IL-10 has also been reported [61, 63]. In
additiontoenhancingtheprobabilityforMSCgraftsurvival,
this immunomodulatory eﬀect of MSCs may also play a
role in IVD regeneration by modifying the environment
from a proinﬂammatory, catabolic condition to a more anti-
inﬂammatory, anabolic environment [4–6, 24, 64, 65].
Several studies have now conﬁrmed the eﬀectiveness
of MSC transplantation, demonstrating that MSCs trans-
planted into degenerating IVDs in vivo can survive, prolif-
erate, and diﬀerentiate into cells expressing the phenotype of
NP cells with suppression of inﬂammatory genes [35].
There are a large number of diﬀerent types of stem
cells and a variety of possible sources of MSCs including
bone marrow, adipose tissue, and other tissues that have
received signiﬁcant attention as potential sources of cells to
repopulate and regenerate the IVD.
Bone marrow aspiration, which has been used by spinal
surgeonsinfusionprocedures,isanexcellentsourceofMSCs
[24]. When bone-marrow-derived stem cells (BSCs) com-
bined with a hyaluronic acid-derived scaﬀold were injected
into pig IVD, IVDs presented a central NP-like region. This
ﬁnding suggested that BSC are able to diﬀerentiate in IVD-
similar cells and also to produce matrix proteins similar
to normal IVD tissues [66]. Further conﬁrmation comes
from experiments performed in previously degenerated or
degraded IVDs in rabbits, that showed how, following
transplantation in these IVDs, BSCs were able to proliferate
and diﬀerentiate into cells expressing and producing some of
the main, although not all, extracellular components of the
IVD [67].
Recently, other stem cells such as synovial MSCs have
been studied as a potential source of cells to be used for
IVD-d. In an induced IVD-d model in rabbits, allogenic
synovial MSCs have been transplanted and evaluated up
to 24 weeks postoperatively with imaging analyses such as
magnetic resonance imaging, radiographs, and histological
analysis. T2-weighted MR imaging revealed a higher signal
intensity of the NP in the MSC group. Radiographs showed
that the height of IVD in the MSC group remained higher
compared to that in the degeneration group. Immunohis-
tochemical analyses showed a higher expression of type II
collagen around NP cells in the MSC group compared to
that of the normal group. These results brought to the
conclusion that synovial MSCs injected into the NP space
promote synthesis of the remaining NP cells to type II
collagen as well as inhibition of degrading enzymes and
inﬂammatorycytokinesexpression,resultinginthestructure
of the intervertebral IVD being maintained [68].Stem Cells International 5
Several authors have recently reported their successful
results using diﬀerent types of stem cells, but there is
still a lack of published evidence regarding adipose-derived
stem cells (ASCs) implantation for IVD degeneration man-
agement, and, only recently, experiments with ASC have
conﬁrmed this type of stem cells as another potential cell
source for IVD repair and regeneration. In fact, in a goat
ABC chondroitinase degeneration model [69], ASC can be
beneﬁcial for cell therapy of IVD disease because these cells
are easily isolated compared to other MSCs such as BSCs
[70, 71].
Despite the promising results deriving from animal
studies, there is still a lack of studies performed in humans.
To our knowledge, the only trial conducted in humans, a
nonrandomized, noncontrolled study evaluating autologous
hematopoietic stem cells transplanted into IVD for the
treatment of low back pain in 10 patients, did not report any
signiﬁcant improvement of the patients’ condition [72].
Therefore, further research and randomized controlled
studies are required for a better deﬁnition of the eﬀectiveness
of the administration of ASC, rather than BSC or other types
of stem cells for the management of IVD degeneration.
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